|
【结 构 式】 
|
【药物名称】Frakefamide, SPD-759, LEF-576, BCH-3963 【化学名称】L-Tyrosyl-D-alanyl-L-(4-fluoro)phenylalanyl-L-phenylalanylamide 【CA登记号】188196-22-7, 244072-12-6 (hydrochloride) 【 分 子 式 】C30H34FN5O5 【 分 子 量 】563.63438 |
【开发单位】Shire BioChem (Originator) 【药理作用】ANALGESIC AND ANESTHETIC DRUGS, Analgesic Drugs, Opioid Analgesics |
合成路线1
The title compound has been prepared by solid-phase peptide synthesis on a Knorr resin. N-Fmoc-L-Phenylalanine (I) is attached to the resin by means of BOP and HOBt, producing resin (II). Deprotection of the N-Fmoc group of (II) with piperidine in DMF gives the phenylalanine-bound resin (III). Subsequent coupling with N-Fmoc-L-p-fluorophenylalanine (IV) yields the dipeptide resin (V), which is further deprotected to (VI) with piperidine in DMF. Further coupling-deprotection cycles with N-Fmoc-D-alanine (VII) and N-Fmoc-O-tert-butyl-L-tyrosine (IX) provide the peptide resins (VIII) and (X) respectively. Finally, simultaneous cleavage from the resin and side chain deprotection is accomplished by treatment with trifluoroacetic acid.
| 【1】 Wang, W. (AstraZeneca plc); Novel opioid peptides. EP 0845003; JP 1999512086; US 6337319; WO 9707130 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 19030 | (2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-3-phenylpropionic acid; N-((9H-fluoren-9-ylmethoxy)carbonyl)-phenylalanine | 35661-40-6 | C24H21NO4 | 详情 | 详情 |
| (II) | 19031 | 9H-fluoren-9-ylmethyl (1S)-2-amino-1-benzyl-2-oxoethylcarbamate | C24H22N2O3 | 详情 | 详情 | |
| (III) | 19032 | (2S)-2-amino-3-phenylpropanamide | 5241-58-7 | C9H12N2O | 详情 | 详情 |
| (IV) | 61042 | (2S)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-3-(4-fluorophenyl)propanoic acid | C24H20FNO4 | 详情 | 详情 | |
| (V) | 61043 | 9H-fluoren-9-ylmethyl (1S)-2-{[(1S)-2-amino-1-benzyl-2-oxoethyl]amino}-1-(4-fluorobenzyl)-2-oxoethylcarbamate | C33H30FN3O4 | 详情 | 详情 | |
| (VI) | 61044 | (2S)-2-amino-N-[(1S)-2-amino-1-benzyl-2-oxoethyl]-3-(4-fluorophenyl)propanamide | C18H20FN3O2 | 详情 | 详情 | |
| (VII) | 19926 | (2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]propionic acid | C18H17NO4 | 详情 | 详情 | |
| (VIII) | 61045 | (2S)-N-[(1S)-2-amino-1-benzyl-2-oxoethyl]-2-{[(2R)-2-aminopropanoyl]amino}-3-(4-fluorophenyl)propanamide | C21H25FN4O3 | 详情 | 详情 | |
| (IX) | 18858 | (2S)-3-[4-(tert-butoxy)phenyl]-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]propionic acid | C28H29NO5 | 详情 | 详情 | |
| (X) | 61046 | (2S)-2-amino-N-((1R)-2-{[(1S)-2-{[(1S)-2-amino-1-benzyl-2-oxoethyl]amino}-1-(4-fluorobenzyl)-2-oxoethyl]amino}-1-methyl-2-oxoethyl)-3-[4-(tert-butoxy)phenyl]propanamide | C34H42FN5O5 | 详情 | 详情 |
合成路线2
In a different strategy, N-Cbz-p-fluorophenylalanine (I) is activated as the mixed anhydride (II) employing isobutyl chloroformate and N-methylmorpholine. Coupling of anhydride (II) with phenylalanine methyl ester (III) leads to the dipeptide ester (IV), which is further treated with methanolic ammonia to produce amide (V). The dipeptide amide (V) is alternatively obtained by direct coupling of mixed anhydride (II) with phenylalanine amide (VI). Hydrogenolysis of the N-Cbz group of (V) in the presence of Pd/C furnishes the deprotected dipeptide (VII).
| 【1】 Franzen, H.M.; Bessidskaia, G.; Abedi, V.; Nilsson, A.; Nilsson, M.; Olsson, L.; Frakefamide, an analgesic tetrapeptide: Development of a pilot-plant-scale process. Org Process Res Dev 2002, 6, 6, 788. |
| 【2】 Franzen, H. (AstraZeneca plc); Process for the preparation of a tetrapeptide. WO 9947548 . |
| 【3】 Nilsson, M.; Ellburg, M.; Franzen, H. (AstraZeneca AB); A process for the preparation of H-Tyr-D-Ala-Phe(F)-Phe-NH2. EP 1212350; JP 2003509437; WO 0119849 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 61047 | (2S)-2-{[(benzyloxy)carbonyl]amino}-3-(4-fluorophenyl)propanoic acid | C17H16FNO4 | 详情 | 详情 | |
| (II) | 61048 | C22H24FNO6 | 详情 | 详情 | ||
| (III) | 12324 | methyl (2R)-2-amino-3-phenylpropanoate | 21685-51-8 | C10H13NO2 | 详情 | 详情 |
| (IV) | 61049 | methyl (2S)-2-{[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-(4-fluorophenyl)propanoyl]amino}-3-phenylpropanoate | C27H27FN2O5 | 详情 | 详情 | |
| (V) | 61050 | benzyl (1S)-2-{[(1S)-2-amino-1-benzyl-2-oxoethyl]amino}-1-(4-fluorobenzyl)-2-oxoethylcarbamate | C26H26FN3O4 | 详情 | 详情 | |
| (VI) | 19032 | (2S)-2-amino-3-phenylpropanamide | 5241-58-7 | C9H12N2O | 详情 | 详情 |
| (VII) | 61044 | (2S)-2-amino-N-[(1S)-2-amino-1-benzyl-2-oxoethyl]-3-(4-fluorophenyl)propanamide | C18H20FN3O2 | 详情 | 详情 |
合成路线3
N-Cbz-D-Alanine (VIII) is activated as the mixed anhydride (IX) and subsequently coupled to the dipeptide amide (VII), producing (X). Deprotection of the N-Cbz group of tripeptide (X) by hydrogenolysis over Pd/C yields (XI). The mixed anhydride (XIII) (prepared from N-Cbz-L-tyrosine (XII) and isobutyl chloroformate) is then coupled to tripeptide (XI), producing (XIV). Finally, removal of the N-Cbz group of (XIV) by catalytic hydrogenolysis furnishes the title compound.
| 【1】 Franzen, H. (AstraZeneca plc); Process for the preparation of a tetrapeptide. WO 9947548 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (VII) | 61044 | (2S)-2-amino-N-[(1S)-2-amino-1-benzyl-2-oxoethyl]-3-(4-fluorophenyl)propanamide | C18H20FN3O2 | 详情 | 详情 | |
| (VIII) | 61209 | CBZ-L-Alanine; (2S)-2-[[(Benzyloxy)carbonyl]amino]propionic acid; N-((Phenylmethoxy)carbonyl)-alanine; Carbobenzyloxy-L-alanine | C11H13NO4 | 详情 | 详情 | |
| (IX) | 61210 | C16H21NO6 | 详情 | 详情 | ||
| (X) | 61211 | benzyl (1R)-2-{[(1S)-2-{[(1S)-2-amino-1-benzyl-2-oxoethyl]amino}-1-(4-fluorobenzyl)-2-oxoethyl]amino}-1-methyl-2-oxoethylcarbamate | C29H31FN4O5 | 详情 | 详情 | |
| (XI) | 61045 | (2S)-N-[(1S)-2-amino-1-benzyl-2-oxoethyl]-2-{[(2R)-2-aminopropanoyl]amino}-3-(4-fluorophenyl)propanamide | C21H25FN4O3 | 详情 | 详情 | |
| (XII) | 39328 | (2S)-2-[[(benzyloxy)carbonyl]amino]-3-(4-hydroxyphenyl)propionic acid | C17H17NO5 | 详情 | 详情 | |
| (XIII) | 61212 | C22H25NO7 | 详情 | 详情 | ||
| (XIV) | 61213 | (1R)-2-{[(1S)-2-{[(1S)-2-amino-1-benzyl-2-oxoethyl]amino}-1-(4-fluorobenzyl)-2-oxoethyl]amino}-1-methyl-2-oxoethyl (2S)-2-{[(benzyloxy)carbonyl]amino}-3-(4-hydroxyphenyl)propanoate | C38H39FN4O8 | 详情 | 详情 |
合成路线4
In an alternative procedure, N-Cbz-L-tyrosine (I) is condensed with D-alanine methyl ester (II), either employing TBTU as the coupling reagent or via previous activation as the mixed anhydride with isobutyl chloroformate, to produce dipeptide (III). After alkaline hydrolysis of the methyl ester function of (III), the resultant carboxylic acid (IV) is coupled to dipeptide amide (V) yielding the protected tetrapeptide (VI). Finally, deprotection of (VI) is carried out by catalytic hydrogenolysis over Pd/C.
| 【1】 Franzen, H.M.; Bessidskaia, G.; Abedi, V.; Nilsson, A.; Nilsson, M.; Olsson, L.; Frakefamide, an analgesic tetrapeptide: Development of a pilot-plant-scale process. Org Process Res Dev 2002, 6, 6, 788. |
| 【2】 Nilsson, M.; Ellburg, M.; Franzen, H. (AstraZeneca AB); A process for the preparation of H-Tyr-D-Ala-Phe(F)-Phe-NH2. EP 1212350; JP 2003509437; WO 0119849 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 39328 | (2S)-2-[[(benzyloxy)carbonyl]amino]-3-(4-hydroxyphenyl)propionic acid | C17H17NO5 | 详情 | 详情 | |
| (II) | 20694 | methyl (2S)-2-aminopropanoate | C4H9NO2 | 详情 | 详情 | |
| (III) | 61214 | methyl (2R)-2-{[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-(4-hydroxyphenyl)propanoyl]amino}propanoate | C21H24N2O6 | 详情 | 详情 | |
| (IV) | 61215 | (2R)-2-{[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-(4-hydroxyphenyl)propanoyl]amino}propanoic acid | C20H22N2O6 | 详情 | 详情 | |
| (V) | 61044 | (2S)-2-amino-N-[(1S)-2-amino-1-benzyl-2-oxoethyl]-3-(4-fluorophenyl)propanamide | C18H20FN3O2 | 详情 | 详情 | |
| (VI) | 61216 | benzyl (1S)-2-[((1R)-2-{[(1S)-2-{[(1S)-2-amino-1-benzyl-2-oxoethyl]amino}-1-(4-fluorobenzyl)-2-oxoethyl]amino}-1-methyl-2-oxoethyl)amino]-1-(4-hydroxybenzyl)-2-oxoethylcarbamate | C38H40FN5O7 | 详情 | 详情 |